Insights

Why Novavax Stock Is Plunging Again Today

What happened
Shares of Novavax (NASDAQ: NVAX) were plunging for a second consecutive day on Wednesday and were down 14.1% as of 12:24 p.m. ET. Today’s downturn is a continuation of a sell-off stemming from investors’ worries about sales of Novavax’s COVID-19 vaccine.
The company missed Wall Street’s estimates with its first-quarter results. It maintained its full-year 2022 revenue guidance of between $4 billion and $5 billion. However, it also noted that Gavi, an alliance focused on distributing COVID vaccines to low- and middle-income countries, is seeking to revise the number of doses ordered and the timing for shipment.
So what
There is a reason for concern about Novavax’s ability to meet its 2022 revenue guidance. So far, the company hasn’t received any orders from Gavi. Some countries are experiencing a supply glut of vaccine doses. Gavi’s desire to change the terms of its deal with Novavax is a reflection of this.
But a good case could be made that Novavax’s valuation already has this uncertainty baked into the share price. The vaccine stock trades at less than 1.7 times expected earnings. Its market cap of $3.6 billion is less than the low end of its revenue outlook range.
Image source: Getty Images.

Now what
Investors will obviously want to watch what happens with Gavi. But Novavax could have a positive catalyst before anything happens on that front. The Food and Drug Administration has scheduled an advisory committee meeting for June 7 to review the Emergency Use Authorization filing for the company’s COVID-19 vaccine.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Novavax (NASDAQ: NVAX) were plunging for a second consecutive day on Wednesday and were down 14.1% as of 12:24 p.m. ET. Today’s downturn is a continuation of a sell-off stemming from investors’ worries about sales of Novavax’s COVID-19 vaccine.

The company missed Wall Street’s estimates with its first-quarter results. It maintained its full-year 2022 revenue guidance of between $4 billion and $5 billion. However, it also noted that Gavi, an alliance focused on distributing COVID vaccines to low- and middle-income countries, is seeking to revise the number of doses ordered and the timing for shipment.

So what

There is a reason for concern about Novavax’s ability to meet its 2022 revenue guidance. So far, the company hasn’t received any orders from Gavi. Some countries are experiencing a supply glut of vaccine doses. Gavi’s desire to change the terms of its deal with Novavax is a reflection of this.

But a good case could be made that Novavax’s valuation already has this uncertainty baked into the share price. The vaccine stock trades at less than 1.7 times expected earnings. Its market cap of $3.6 billion is less than the low end of its revenue outlook range.

Image source: Getty Images.

Now what

Investors will obviously want to watch what happens with Gavi. But Novavax could have a positive catalyst before anything happens on that front. The Food and Drug Administration has scheduled an advisory committee meeting for June 7 to review the Emergency Use Authorization filing for the company’s COVID-19 vaccine.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!